Prothena Rally Continues; Gains 12%

Shares of Prothena Corp. plc (PRTA) are gaining over 12% on Friday morning despite no stock-related news statement from the company.

PRTA is currently trading at $62.25, up $7.03 or 12.73%, on the Nasdaq. The stock has traded between $9.67 and $63.00 in the past 52 week period. The stock has gained over 55% in the past one month and has surged over 415% in the year to date period.

Last month, Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to enter into an exclusive U.S. license for PRX005. Bristol Myers will pay Prothena $80 million.

Prothena is a late-stage clinical company that focuses on discovery and development of novel therapies for life-threatening diseases in the US.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Follow RTT